{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Bortezomib 1.3 mg/m2 days 1, 8, 15, 22; Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23; Melphalan 9 mg/m2/day days 1-4\n\nbortezomib: Bortezomib 1.3 mg/m2 days 1, 8, 15, 22\n\ndexamethasone: Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23\n\nmelphalan: Melphalan 9 mg/m2/day days 1-4\n\nmicroarray analysis: ≤28 days prior to enrollment\n\nflow cytometry: Day 1 of cycles 6, 12, 18 and at end of study.\n\nlaboratory biomarker analysis: ≤28 days prior to enrollment\n\nquality-of-life assessment: Start of each cycle","id":"OG000","title":"Melphalan, Dexamethasone, Bortezomib,"}],"populationDescription":"Not collected not analyzed.","reportingStatus":"POSTED","timeFrame":"Beginning of cycles 4, 8, 12, 16 and 20, at follow up and end of study.","title":"Overall Hematologic Response Rate (OHR)","type":"SECONDARY"}